Josh Levitsky1, Joshua Miller, Xuemei Huang, Dhivya Chandrasekaran, Li Chen, James M Mathew. 1. 1 Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 2 Department of Surgery, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL. 3 Jesse Brown VA Medical Center, Chicago, IL. 4 Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
BACKGROUND: It is unclear if new costimulatory blockade agents, such as the cytotoxic T lymphocyte-associated antigen 4-Ig molecule belatacept (BEL), promote or inhibit the potential for immunologic tolerance in transplantation. We therefore tested the in vitro effects of BEL on human regulatory T cells (Tregs) in mixed lymphocyte reactions (MLR) alone and in combination with maintenance agents used in transplant recipients. METHODS: BEL, mycophenolic acid (MPA), and sirolimus, either alone or in combination, were added to healthy volunteer Treg-MLR, testing (a) H-TdR incorporation for inhibition of lymphoproliferation and (b) flow cytometry to analyze for newly generated CD4+ CD25(high) FOXP3+ Tregs in carboxyfluorescein succinimidyl ester-labeled MLR responders. In addition, the modulatory effects of putative Tregs generated in the presence of these drugs were also tested using the lymphoproliferation and flow cytometric assays. RESULTS: In comparison with medium controls, BEL dose-dependently inhibited both lymphoproliferation and Treg generation in human leukocyte antigen DR matched and mismatched MLRs either alone or in combination with MPA or sirolimus. However, MPA alone inhibited lymphoproliferation but significantly enhanced Treg generation at subtherapeutic concentrations (P<0.01). In addition, purified CD4+ CD127- cells generated in MLR in the presence of MPA and added as third component modulators in fresh MLRs significantly enhanced newly developed Tregs in the proliferating responder cells compared with those generated with BEL or medium controls. CONCLUSIONS: BEL alone and in combination with agents used in transplant recipients inhibits the in vitro generation of human Tregs. BEL might therefore be a less optimal agent for tolerance induction in human organ transplantation.
BACKGROUND: It is unclear if new costimulatory blockade agents, such as the cytotoxic T lymphocyte-associated antigen 4-Ig molecule belatacept (BEL), promote or inhibit the potential for immunologic tolerance in transplantation. We therefore tested the in vitro effects of BEL on human regulatory T cells (Tregs) in mixed lymphocyte reactions (MLR) alone and in combination with maintenance agents used in transplant recipients. METHODS: BEL, mycophenolic acid (MPA), and sirolimus, either alone or in combination, were added to healthy volunteer Treg-MLR, testing (a) H-TdR incorporation for inhibition of lymphoproliferation and (b) flow cytometry to analyze for newly generated CD4+ CD25(high) FOXP3+ Tregs in carboxyfluorescein succinimidyl ester-labeled MLR responders. In addition, the modulatory effects of putative Tregs generated in the presence of these drugs were also tested using the lymphoproliferation and flow cytometric assays. RESULTS: In comparison with medium controls, BEL dose-dependently inhibited both lymphoproliferation and Treg generation in human leukocyte antigen DR matched and mismatched MLRs either alone or in combination with MPA or sirolimus. However, MPA alone inhibited lymphoproliferation but significantly enhanced Treg generation at subtherapeutic concentrations (P<0.01). In addition, purified CD4+ CD127- cells generated in MLR in the presence of MPA and added as third component modulators in fresh MLRs significantly enhanced newly developed Tregs in the proliferating responder cells compared with those generated with BEL or medium controls. CONCLUSIONS: BEL alone and in combination with agents used in transplant recipients inhibits the in vitro generation of humanTregs. BEL might therefore be a less optimal agent for tolerance induction in human organ transplantation.
Authors: Christian P Larsen; Thomas C Pearson; Andrew B Adams; Paul Tso; Nozomu Shirasugi; Elizabeth Strobert; Dan Anderson; Shannon Cowan; Karen Price; Joseph Naemura; John Emswiler; JoAnne Greene; Lori Ann Turk; Jurgen Bajorath; Robert Townsend; David Hagerty; Peter S Linsley; Robert J Peach Journal: Am J Transplant Date: 2005-03 Impact factor: 8.086
Authors: Thangamani Muthukumar; Darshana Dadhania; Ruchuang Ding; Catherine Snopkowski; Rubina Naqvi; Jun B Lee; Choli Hartono; Baogui Li; Vijay K Sharma; Surya V Seshan; Sandip Kapur; Wayne W Hancock; Joseph E Schwartz; Manikkam Suthanthiran Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Carla C Baan; Barbara J van der Mast; Mariska Klepper; Wendy M Mol; Annemiek M A Peeters; Sander S Korevaar; Aggie H M M Balk; Willem Weimar Journal: Transplantation Date: 2005-07-15 Impact factor: 4.939
Authors: Natalia Nikolaeva; Frederike J Bemelman; Si-La Yong; René A W van Lier; Ineke J M ten Berge Journal: Transplantation Date: 2006-02-15 Impact factor: 4.939
Authors: Joseph R Leventhal; Joshua Miller; James M Mathew; Sunil Kurian; Anat R Tambur; John Friedewald; Jane Charrette; Michael M Abecassis Journal: Hum Immunol Date: 2018-02-01 Impact factor: 2.850
Authors: Sangho Lim; Nancy C Kirkiles-Smith; Jordan S Pober; Alfred L M Bothwell; Je-Min Choi Journal: Biomaterials Date: 2018-08-21 Impact factor: 12.479